Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for problems caused by androgen deprivation therapy in prostate cancer patients
IRCT20180722040556N5Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in prostate cancer (PCa) and androgen deprivation therapy-related symptoms, sponsored by Isfahan University of Medical Sciences. Started May 2020; status: completed.
02
Drugs
melatonin
03
Conditions
prostate cancer (PCa)androgen deprivation therapy-related symptoms
Beyond the preview
Go deeper on IRCT20180722040556N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180722040556N5.